Dr. YongTae Kim, the founding CEO of Mepsgen, is an Associate Professor in Bioengineering of the George W. Woodruff School of Mechanical Engineering an Adjunct Professor of the Wallace H. Coulter Department of Biomedical Engineering at Georgia Institute of Technology.

He co-founded Mepsgen with Dr. Robert Langer who has been being an amazing advisor in his academic career since he was a Postdoctoral Associate in the Langer Laboratory of the David H. Koch Institute for Integrative Cancer Research at MIT.

He has won the highly competitive and prestigious NIH Director’s New Innovator Award, NSF CAREER Award, and AHA National Scientist Development Grant Award.

He was also selected as the Korean Ministry of Science and ICT Awardee in Nano Research.

Sung Jae Min is the CBO of MEPSGEN, and he is in charge of business & sales for microengineered 3D human organ model platforms for advanced pharmaceutical development.

Also, he is an expert in B2B business with 23+ years of experience in sales for solution/platform/consulting/IT service/business outsourcing.

Hayoung Lee has served as MEPSGEN’s Chief Strategy Officer since November 2023. Before joining the company, she served as Chief IR Officer of the US based immuno-oncology drug development company NeoImmuneTech, and as head of IR for a Korean botox and filler company Hugel and for Doosan E&C.

Over 20 years of experiences, she has led or involved in numerous corporate strategic projects such as cross-border M&A, strategic alliances, IPO, USD based bond issuance, attracting equity investors from global sovereign funds, pension funds, and long funds.

Mepsgen provides a tool for developing new drugs as a chip platform technology.  In addition, it is strongly believed that Nanoparticles prepared by Mepsgen will be developed as a new drug in the near future.  she is a chief legal officer of Mepsgen and Korean patent attorney. 

She had her undergraduate degree in pharmacy from Seoul National University and received degree in intellectual property law from University of London, Queen Mary.

She also has a lot of experiences in consulting multinational pharmaceutical companies in the field of intellectual property, drug approval and drug pricing while working for Kim and Chang, one of the largest Korean law firms.

As Chief Scientific Officer at MEPSGEN, Dr. Hyuck Kim takes care of R&D for new drug discovery to treat neurodegenerative disease and cancer.

He received a Ph.D. in Interdisciplinary Program in Neuroscience from Seoul National University, then completed his postdoctoral research at Rutgers University and the University of Minnesota.

He has spent much of his career understating the mechanism of autism and Huntington’s disease, the use of hMSCs-derived exosomes in the treatment of neurodegenerative disease, and epigenetic alterations of skin and prostate cancer.

Dr. Hoon Suk Rho is the CTO of MEPSGEN, and he is in charge of developing microengineered 3D human organ model platforms for advanced pharmaceutical development.

Also, he is an expert in microfluidic technology and microelectromechanical systems (MEMS) who has more than 15 years of experience in developing microfluidic devices for biological and biotechnological applications, e.g., cell culture, separation and analysis of circulating tumor cells, and recapitulating 3D human organ models. He received his Ph.D. from the MESA+ Institute for Nanotechnology at the University of Twente in the Netherlands.

Robert Langer, MD, PhD, is one of 12 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member. Dr. Langer has written more than 1,500 articles. He also has over 1,400 issued and pending patents worldwide.

Allan Levey, MD, PhD, is a professor and chair of the Department of Neurology at Emory University's School of Medicine, as well as the director of Emory's Alzheimer's Disease Research Center. (https://alzheimers.emory.edu/)